TCM
EBS icon

Triumph Capital Management’s Emergent Biosolutions EBS Stock Holding History

Triumph Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87K Hold
700
– – ﹤0.01% 1304
2026
Q1 		$5.81K Hold
700
– – ﹤0.01% 1262
2025
Q4 		$8.65K Buy
+700
New +$7.5K ﹤0.01% 1123

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Triumph Capital Management's EBS Position: Q2 2026 in Review

Triumph Capital Management held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 700 shares worth $5.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Triumph Capital Management first reported a position in EBS in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.65K in Q4 2025. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Triumph Capital Management held 700 shares of Emergent Biosolutions worth $5.87K as of Q2 2026.
  • Triumph Capital Management left its Emergent Biosolutions share count unchanged in Q2 2026.
  • Emergent Biosolutions made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1304 holding.
  • Triumph Capital Management first reported a position in Emergent Biosolutions in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's Emergent Biosolutions position peaked at $8.65K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.